Saturday 17 October 2026
Export SGMT’s income statement to Excel — free account
Sagimet Biosciences Inc.
SGMT Healthcare Biotechnology
Sagimet Biosciences Inc.’s revenue for fiscal 2023 (year ended December 2023) was $2.0 million. In the quarter to June 2026, EPS grew 18.8% and free cash flow fell 22.0%, each against the same quarter a year earlier.
8.02
0.15
−1.84%
Follow SGMT
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Trend | 2026e | 2027e | 2028e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price, $ | |||||||||||||||
| Price, $ | Low | — | — | — | — | — | — | — | 2.13 | 2.39 | 1.73 |
Analyst estimates 2026–2028 Powerpack |
|||
| High | — | — | — | — | — | — | — | 18.33 | 20.71 | 11.41 | |||||
| People | |||||||||||||||
| People | Employees | — | — | — | — | — | — | 10 | 10 | 14 | 16 | ||||
| Revenue/emp, $m | — | — | — | — | — | — | 0.00 | 0.20 | 0.00 | 0.00 | |||||
| Income, $m | |||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | 2 | — | — | ||||
| Gross margin, % | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 100.00 | — | — | |||||
| EBT | — | — | — | (14) | (11) | (24) | (30) | (28) | (46) | (51) | |||||
| EBT margin, % | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | (1,393.80) | 0.00 | 0.00 | |||||
| Net income | — | — | — | (14) | (11) | (24) | (30) | (28) | (46) | (51) | |||||
| Depreciation | — | — | — | 0 | 0 | 0 | 0 | 0 | (1) | 0 | |||||
| Per share, $ | |||||||||||||||
| Per share, $ | Revenue | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.19 | 0.00 | 0.00 | ||||
| Earnings | — | — | — | (0.67) | (0.53) | (1.14) | (165.20) | (2.66) | (1.45) | (1.58) | |||||
| Cash flow | — | — | — | (0.49) | (0.49) | (1.02) | (132.67) | (2.27) | (1.35) | (1.41) | |||||
| Capex | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Free cash flow | — | — | — | (0.49) | (0.49) | (1.02) | (132.67) | (2.27) | (1.35) | (1.41) | |||||
| Book value | — | — | — | 0.41 | 3.13 | 2.64 | (1,012.73) | 8.71 | 4.97 | 3.44 | |||||
| Shares, m | — | — | — | 21 | 21 | 21 | 0 | 10 | 31 | 32 | |||||
| Valuation, × | |||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | 0.00 | — | — | ||||
| P/S | — | — | — | — | — | — | — | 0.00 | — | — | |||||
| P/B | — | — | — | — | — | — | — | 0.61 | — | — | |||||
| EV/Sales | — | — | — | — | — | — | — | 0.00 | — | — | |||||
| EV/FCF | — | — | — | — | — | — | — | 1.64 | — | — | |||||
| Cash, $m | |||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | (11) | (10) | (22) | (24) | (24) | (42) | (46) | ||||
| Capex | — | — | — | — | — | — | — | — | — | — | |||||
| Free cash flow | — | — | — | (11) | (10) | (22) | (24) | (24) | (42) | (46) | |||||
| Balance, $m | |||||||||||||||
| Balance, $m | Working capital | — | — | — | 9 | 67 | 55 | 28 | 91 | 148 | 111 | ||||
| Total debt | — | — | — | 0 | 0 | 0 | 0 | — | — | — | |||||
| Net debt | — | — | — | (10) | (68) | (56) | (32) | (95) | (151) | (113) | |||||
| Shareholders’ equity | — | — | — | 9 | 67 | 56 | (187) | 91 | 156 | 111 | |||||
| Returns, % | |||||||||||||||
| Returns, % | ROA | — | — | — | 0.00 | (28.38) | (38.19) | (66.26) | (42.97) | (35.46) | (36.89) | ||||
| ROIC | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | (747.17) | 0.00 | |||||
| ROE | — | — | — | 0.00 | 8.71 | 16.62 | 17.67 | 58.14 | (36.92) | (38.20) | |||||
Negative figures in brackets.
Fiscal years to Dec 2023 · latest quarter Sep 2023
Charts ten years each
Sagimet Biosciences Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| PHAT Phathom Pharmaceuticals, Inc. | $606.8M | — (loss-making) | — (loss-making) | +88.02% (above 0%: growing) | n/m | +96.86% (above 0%: growing) | 79.68% | (5.34%) | Compare |
| OLMA Olema Pharmaceuticals, Inc. | $601.1M | — (loss-making) | — | — | n/m | −54.33% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| CRMD CorMedix Inc | $581.5M | 3.0× | 16.5× | +156.52% (above 0%: growing) | +13.79% (above 0%: growing) | +185.90% (above 0%: growing) | 75.66% | 42.10% | Compare |
| SLN Silence Therapeutics PLC Sponsored ADR | $581.1M | — (loss-making) | — (loss-making) | +197.18% (above 0%: growing) | n/m | +106.95% (above 0%: growing) | 97.39% | 0.00% | Compare |
| SGMT Sagimet Biosciences Inc. | $574.7M | — (loss-making) | — (loss-making) | — | n/m | −21.95% (below 0%: shrinking) | 100.00% | 0.00% | |
| DBVT DBV Technologies S.A. | $572.6M | — (loss-making) | — | −53.33% (below 0%: shrinking) | n/m | −56.15% (below 0%: shrinking) | 100.00% | (7,228.57%) | Compare |
| VALN Valneva SE Sponsored ADR | $560.4M | 59.7× | 19.4× | −17.29% (below 0%: shrinking) | n/m | −56.05% (below 0%: shrinking) | 15.29% | (76.67%) | Compare |
| STTK Shattuck Labs, Inc. | $555.0M | — (loss-making) | — (loss-making) | −10.31% (below 0%: shrinking) | n/m | +1.01% (above 0%: growing) | 100.00% | 0.00% | Compare |
| VECT VectivBio Holding AG | $545.5M | — (loss-making) | — (loss-making) | — | n/m | — | 91.93% | 0.00% | Compare |
| Median of peers | $576.8M | — | — | +38.86% | — | +1.01% | 85.81% | 0.00% |
Sagimet Biosciences Inc. (SGMT) key facts
- Sagimet Biosciences Inc. (SGMT) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
- Sagimet Biosciences Inc.’s revenue for fiscal 2023 (year ended December 2023) was $2.0 million.
- As of October 16, 2026, SGMT traded at $8.02, a market capitalization of $574.7 million.
- Return on equity was −38.2% and debt-to-equity 0.00.
- Its Altman Z-score is 2.50 (grey zone) for fiscal 2023.